Berlin-based Inuru announced that it has raised $10M (€9.5M), underscoring the growing confidence in the company’s cost-efficient OLED (Organic Light-Emitting Diode) technology.
The fund comes from Aper Ventures, Adamed Technology (the venture capital arm of Polish pharmaceutical company Adamed Pharma), ARIA, and a group of business angels.
While OLED technology offers several advantages, its high manufacturing costs have limited its widespread use. This recent infusion of investor support will enable Inuru to introduce its technology to a broader audience and expand into new industries that can benefit from more visible and interactive labels.
“Adamed’s investment validates the pressing need for improved medication delivery. Our OLED labels empower brands to enhance medication adherence and help patients regain control over their health,” Inuru CEO Marcin Ratajczak says.